Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Oct 15;27(20):2192-206.
doi: 10.1101/gad.225334.113.

Epithelial-mesenchymal plasticity in carcinoma metastasis

Jeff H Tsai  1 , Jing Yang
Affiliations
Review

Epithelial-mesenchymal plasticity in carcinoma metastasis

Jeff H Tsai et al. Genes Dev. .

Abstract

Tumor metastasis is a multistep process by which tumor cells disseminate from their primary site and form secondary tumors at a distant site. Metastasis occurs through a series of steps: local invasion, intravasation, transport, extravasation, and colonization. A developmental program termed epithelial-mesenchymal transition (EMT) has been shown to play a critical role in promoting metastasis in epithelium-derived carcinoma. Recent experimental and clinical studies have improved our knowledge of this dynamic program and implicated EMT and its reverse program, mesenchymal-epithelial transition (MET), in the metastatic process. Here, we review the functional requirement of EMT and/or MET during the individual steps of tumor metastasis and discuss the potential of targeting this program when treating metastatic diseases.

Keywords: carcinoma metastasis; epithelial–mesenchymal transition (EMT); extravasation; intravasation; invasion; mesenchymal–epithelial transition (MET); tumor dormancy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Model for reversible EMT over time. Epithelial cells undergo genetic transformation to become carcinoma in situ. Microenvironmental and genetic factors can promote the malignant conversion of these cells to activate the EMT program. During these early stages of tumor development, tumor cells that have undergone EMT can invade the local matrix (step I) and intravasate into the vasculature (step II). These epithelial–mesenchymal-transitioned cells are then transported in the circulation and survive via various prosurvival mechanisms (step III). At the distant tissue site, maintenance of the EMT program is required to help tumor cells extravasate into the parenchyma (step IV) to establish micrometastases. This initial seeding of tumor cells at distant sites can occur rapidly, after which cells may remain “dormant” for a long period of time. Subsequent colonization in distant organs requires the reversion of EMT and/or activation of the MET program to establish secondary tumors (step V).
Figure 2.
Figure 2.
EMT in local invasion and intravasation. Activation of the EMT program is mostly characterized by the loss of E-cadherin expression. In order to invade through local basement membrane (surrounding the tumor or the tumor vasculature), these mesenchymal tumor cells up-regulate several secreted (MMPs) and membrane-tethered (MT-MMPs) proteases to break down ECM components. In addition, EMT factors can up-regulate specialized cellular structures such as invadopodia to promote local invasion. Expression of proteases can further induce EMT by breaking down cell–cell junctions, resulting in a positive feedback loop during malignant transformation of these cells.
Figure 3.
Figure 3.
EMT in systemic transport and extravasation. Experimental and clinical samples have revealed an EMT signature in CTCs. This signature provides a possible biomarker to monitor tumor progression and/or therapeutic response. Experimental evidence suggests that platelets play a critical role in maintaining EMT activation in CTCs by providing the TGF-β signal. Furthermore, studies suggest that activation of EMT promotes microtentacle formation that allows tumor cell attachment to the endothelium and promotes cell survival. In order to extravasate at distant sites, tumor cells maintain an EMT phenotype and express cellular protrusions that allow extravasation, which is mediated by β1 integrin signaling.
Figure 4.
Figure 4.
Mechanisms of EMT reversion. Colonization at distant sites requires the reversion of EMT to promote tumor cell proliferation. The interplay between EMT activators and inhibitors (i.e., MET activators) plays a critical role in metastatic outgrowth. The loss of EMT activators such as Twist1 or Prrx1 appears to be required to promote EMT reversion. However, signals from the microenvironment in distant sites may also shift the balance from EMT activators to EMT inhibitors or MET activators. It is unknown when or how these factors are regulated during tumor progression, which may impact treatment of metastatic disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S 2009. Stem cell and epithelial–mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11: R46. - PMC - PubMed
    1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci 100: 3983–3988 - PMC - PubMed
    1. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, et al. 2008. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell 14: 79–89 - PubMed
    1. Bachelder RE, Yoon SO, Franci C, de Herreros AG, Mercurio AM 2005. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: Implications for the epithelial–mesenchymal transition. J Cell Biol 168: 29–33 - PMC - PubMed
    1. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, Sheppard D, Oettgen P, Mercurio AM 2005. Transcriptional activation of integrin β6 during the epithelial–mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. J Clin Invest 115: 339–347 - PMC - PubMed

Publication types

MeSH terms